2023
SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity
Jaycox J, Lucas C, Yildirim I, Dai Y, Wang E, Monteiro V, Lord S, Carlin J, Kita M, Buckner J, Ma S, Campbell M, Ko A, Omer S, Lucas C, Speake C, Iwasaki A, Ring A. SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity. Nature Communications 2023, 14: 1299. PMID: 36894554, PMCID: PMC9996559, DOI: 10.1038/s41467-023-36686-8.Peer-Reviewed Original ResearchConceptsVaccine-associated myocarditisAutoimmune patientsAutoantibody reactivitySARS-CoV-2 mRNA vaccinationVaccine-related adverse effectsSARS-CoV-2 immunitySARS-CoV-2 infectionAcute COVID-19Development of autoantibodiesCOVID-19 patientsAnti-viral immunityVirus-specific antibodiesCOVID-19 vaccineCOVID-19Humoral autoimmunityMRNA vaccinationAutoantibody responsePost vaccinationAutoantibody developmentAutoimmune diseasesHumoral responseHealthy individualsPatientsAntigen profilingAdverse effects
2007
Toll-like receptors regulation of viral infection and disease
Thompson JM, Iwasaki A. Toll-like receptors regulation of viral infection and disease. Advanced Drug Delivery Reviews 2007, 60: 786-794. PMID: 18280610, PMCID: PMC2410298, DOI: 10.1016/j.addr.2007.11.003.Peer-Reviewed Original ResearchConceptsToll-like receptorsVirus infectionRole of TLRsProtective anti-viral immunityToll-like receptor regulationAdaptive immune responsesAnti-viral immunityMammalian Toll-like receptorsVirus-induced diseaseViral nucleic acidsStudies of miceTLR activationInteraction of virusImmune responseViral infectionTLR systemTLR proteinsReceptor regulationInfectionDiseaseOutcomesCritical roleMiceImmunityReceptors